Strong emerging rationale for combining oncogene-targeted agents with immunotherapy

In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yan, Lizée, Gregory, Hwu, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601155/
https://www.ncbi.nlm.nih.gov/pubmed/23524978
http://dx.doi.org/10.4161/onci.22730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601155/
https://www.ncbi.nlm.nih.gov/pubmed/23524978
http://dx.doi.org/10.4161/onci.22730

Ejemplares similares